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Objective: Viral load monitoring has been proposed as a tool
to reinforce adherence, but outcomes have never been systemat-
ically assessed.
Design: A meta-analysis was conducted to systematically analyze
the research on viral load monitoring as a tool to reinforce adherence.
Viremic resuppression is deﬁned here as a decrease in viral load
beneath a particular threshold following viral load levels that have
been elevated despite antiretroviral treatment.
Methods: Six databases were searched for studies published up to
November 2012, which reported the use of viral load monitoring as
a tool to identify patients in need of adherence support. Three
conference abstract sites were reviewed for studies reported in the
last 2 years. Randomized and quasi-randomized trials and observa-
tional studies, were eligible. No language or geographical restrictions
were applied.
Results: Six retrospective and 2 prospective observational studies
reported data from 8 countries: South Africa, the United States,
Thailand, Mali, Burkina Faso, Swaziland, India, and France. Five
studies reported on viremic resuppression, with a pooled estimate of
70.5% (95% conﬁdence interval: 56.6% to 84.4%) resuppressed. The
remaining 3 studies all reported declines in mean viral load. Delayed
onset of routine viral load monitoring was associated with the
emergence of drug resistance.
Conclusions: The clear trend of resuppression, following viral load
testing and adherence support, demonstrates the utility of viral load
as a tool to identify patients in need of enhanced adherence support.
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INTRODUCTION
There is an increasing appreciation for the beneﬁts of
routine viral load monitoring as a tool to provide an early
indication of risk for treatment failure and reinforce adher-
ence.1,2 For patients in whom a detectable viral load is the result
of poor adherence, timely identiﬁcation of viremia provides an
opportunity to reinforce adherence before the development of
resistance mutations and, thus, maintain the efﬁcacy of the
patient’s current antiretroviral therapy (ART) regimen.3 Subse-
quent follow-up viral load tests will document whether the
patient is able to achieve viral suppression again4 or if the
patient remains viremic, potentially triggering a genotype test
to document resistance or an empiric regimen change.2
The World Health Organization (WHO)5 recognizes the
importance of regular monitoring, including viral load, for
reinforcing adherence to ART,6 and the 2010 WHO Guide-
lines for ART in resource-limited settings propose an algo-
rithm for using viral load as a means for discriminating
between patients in need of adherence support and those
who require a switch to second-line therapy.5 Recognizing
the beneﬁt of this approach, the 2010 WHO guidelines also
recommend that countries begin to phase in virological mon-
itoring. However, capacity to implement routine viral load
testing remains limited in many resource-constrained settings,
leading to debate about the relative importance of viral load
within a public health approach.7,8
This systematic review assesses the impact of routine
viral load monitoring on achieving virological resuppression
in viremic patients.
METHODS
Using a sensitive search strategy as part of a predeﬁned
protocol (see Appendix S1, Supplemental Digital Content,
http://links.lww.com/QAI/A437), we searched PubMed,
EMBASE, CABS Abstracts, Cochrane Central Register of Con-
trolled Trials, LILACS, and AMED databases up to November
2012 for studies that reported on the targeted use of an adher-
ence intervention following an initial viral load and reported
virological outcomes following the intervention. No language,
date, or geographical exclusions were applied. We further
searched the abstract databases of the International AIDS Soci-
ety, Conferences on Retroviruses and Opportunistic Infections,
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and the MSF Scientiﬁc Day, from 2011 to May 2013, to identify
recent studies that have not yet been published in full. After an
initial title screen, full text copies of potentially eligible articles
were reviewed independently by 2 reviewers. A title search of
references was performed on articles meeting the inclusion cri-
teria to determine potential articles for inclusion, which were not
identiﬁed using the initial database search. After all articles
meeting the inclusion criteria were identiﬁed, data were
abstracted by 2 independent reviewers according to the prespe-
ciﬁed categories. Conﬁrmations were requested from investiga-
tors when needed.
Articles were excluded if they had fewer than 2 viral
load test rounds, if follow-up testing differed greatly between
intervention and control groups (for comparative studies), if
patients were antiretroviral naive or had been started on ART
within the preceding 6 months, or if none of the outcomes of
interest were reported. Viremia was deﬁned based on thresh-
olds deﬁned by the studies. Articles were omitted from the
review if they were judged to be at high risk of bias for the
outcome of interest (ie, if other factors, such as changes in
medication during the study, may have inﬂuenced resuppres-
sion rates). No restrictions were placed on the study design.
For studies reporting the proportion of patients resup-
pressing following an adherence intervention, data were pooled
using random-effects meta-analysis following stabilization of
the variance of raw proportions using a Freeman–Tukey type
arcsine square-root transformation. Studies that did not have
the same outcome measure (proportion resuppressed) were
excluded from the meta-analysis, as these could not be directly
compared statistically. All analyses were conducted using Stata
version 12 (StataCorp, LP, College Station, TX).
RESULTS
Approximately 4279 titles were identiﬁed using the
initial database search and taken for abstract review, of which
183 articles were read in full. Overall, 14 were identiﬁed,
from which 6 met eligibility for the review; 2,047 conference
abstracts were also screened and identiﬁed 2 additional
studies for review (see Appendix S2, Supplemental Digital
Content, http://links.lww.com/QAI/A437). Characteristics
for the studies included are described in Table 1.
The selected studies were published between 2004 and
2013 and reported data from 8 countries: South Africa,9,10 the
United States,11 Thailand,6 Mali and Burkina Faso,12 the King-
dom of Swaziland,13 India,8 and France.14 Five studies reported
outcomes in terms of viremic resuppression in addition to viral
load monitoring.6,9,10,13,15 Follow-up period for the included
studies varied from at least 3 months13,15 to 6 months6,9,10 to
4 years.9 Of the 6 articles identiﬁed from the literature review
for this study, 6 were retrospective cohorts6,8,9,11,13,14 and 2
prospective cohorts.10,12
The studies deﬁned different thresholds for viremia:
.50 copies per milliliter6,8,13; .200 copies per milliliter14;
.400 copies per milliliter9; .500 copies per milliliter12;
and .1000 copies per milliliter10; and 1 did not specify
the viremic threshold.11 Similarly, viremic resuppression
was deﬁned differently: ,50 copies per milliliter6,8,11,12;
,100 copies per milliliter13; ,200 copies per milliliter14;
,400 copies per milliliter9; or ,1000 copies per milliliter.10
Patient characteristics and reporting periods varied
across studies. One study included children and adults,6 and
the rest included adults alone8,10,11,13 or did not specify
age.8,9,12,14 Although 1 prospective cohort collected data from
the onset of treatment, the other 7 provided data starting with
the detection of a raised viral load.6,8,9,11–14 All studies
included patients who had already begun ART. Two studies
noted that all patients had been enrolled in treatment for at
least six months prior to the onset of viral load monitoring.6,12
One study provided additional unpublished data on resuppres-
sion in their cohort.9
There was substantial variability in the type and duration
of adherence support interventions. These interventions
included peer support, adherence counselors, peer counselors,
educational sessions, home visits, adherence support tools, and
short-term directly observed therapy.6,8–12,14
Study quality was assessed according to modiﬁed New-
castle Ottawa criteria (seeAppendix S3, Supplemental Digital
Content, http://links.lww.com/QAI/A437) and was judged
overall to be moderate. Most studies (6) were retrospective
cohorts, but all provided objective outcome measures with
appropriate statistical analysis; 3 discussed sources of bias
and most (5) assessed generalizability of the ﬁndings.
All studies documented reductions in numbers of
viremic patients between the ﬁrst detectable viral load and
subsequent viral loads. These reductions were statistically
signiﬁcant, where such analysis was done. One study reported
data as time to event and estimated that, by 32 months, only
5.6% patients will have failed virologically (2 consecutive
viral load tests over 1000).10 Five studies reported on the
proportion of patients resuppressing after an adherence inter-
vention; this ranged from 54.2% [95% conﬁdence interval
(CI): 46.3% to 62.0%]13 to 89.1% (95% CI 77.8-96.7%),6
with a pooled proportion of 70.46% (95% CI: 56.6% to
84.4%, t2 = 0.11) (Fig. 1). The lowest proportion of resup-
pression was reported by Pirkle et al12 in which only a third of
participants achieved .1 log viral load reduction; however,
this cohort had been on ART an average of 23.7 months
before viral load monitoring was initiated, and there was
a high rate of accumulated ART resistance mutations that
had developed before the adherence intervention. The highest
proportion of resuppression (90%) was reported by a study
that focused on a subset of patients with viremia between
50 and 1000 copies per milliliter.6
DISCUSSION
This review found that, in all studies, the majority of
patients in whom viremia is initially detected resuppress
following an adherence intervention, and all studies showed
a subsequent reduction in viral load levels.
Targeted adherence interventions triggered by viral load
monitoring may allow patients to stay on more affordable, less
complex, ﬁrst-line regimens, with clear beneﬁts for both the
patient and healthcare system.3,16,17 On average, second-line
HIV treatments are at least 3 times the price of ﬁrst-line med-
ications in low-income countries.18 Models predict that up to
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TABLE 1. Description of Interventions and Outcomes
Study Year N Study Design
Viral load
Monitoring Schedule Intervention Outcome (Viremia) Signiﬁcance
Included in
Meta-
Analysis
Berki-
Benhaddad
et al14
2006 15 Retrospective
cohort
Baseline, months 1, 3,
9, and 12.
Personalized
adherence support.
2Log 2.3 decreased
viral load.
P = 0.045
(n = 15)
No
Calmy et al9 2007 232 Retrospective
cohort
(comparative)
Baseline, 3 months, 6
months, and every 6
months thereafter.
Preparedness
counseling,
pillboxes, support
groups, and
a buddy system.
Viral load testing
used to identify
patients who
needed additional
support.
77% patients who
underwent an
adherence
intervention
achieved viral load
resuppression,
deﬁned as viral load
,400 copies/mL
Yes
DeFino et al11 2004 45 Retrospective
cohort
Baseline, months 3, 6,
9, and 12.
6–8 weekly one-on-
one sessions with
a nurse or
counselor. Also
included quarterly
reinforcement,
virological
monitoring,
pillboxes, pictorial
medication
schedules, and
alarm reminders.
Median decrease in
mean viral load
from 180,190 to
49,206 copies/mL.
Resuppression
was deﬁned as
,50 copies/mL.
P = 0.08
(n = 45)
No
Khan et al8 2013 40 Retrospective
cohort
Baseline, 3 months, 6
months.
Structured client-
centered adherence
counseling and
health education for
patients and their
families.
78% of those on
second-line therapy
with an elevated
viral load and 78%
of those
subsequently on
third-line therapy
with an elevated
viral load
resuppressed.
Yes
Orrell et al10 2007 43 Prospective
cohort
Baseline, with testing
every 8 weeks until
resuppression.
Targeted intervention
for those with
elevated viral load,
including pill
boxes, dosing
diaries, 3
educational
sessions, and
counselor home
visits.
53% with viral load
initially .1000
copies/mL reached
full resuppression,
deﬁned as
,50 copies/mL.
Yes
Parker et al13 2013 200 Retrospective
cohort
Baseline, 3 months. Intensiﬁed adherence
counseling.
47.5% patients had
undetectable viral
loads at the second
viral load test.
Yes
Pirkle et al.12 2009 56 Prospective
cohort
Baseline and after
adherence
intervention.
1 month of mDAART
administered along
with weekly follow-
up visits with
a pharmacist or
counselor.
35.7% decreased viral
load 1 log;
resuppression was
not deﬁned.
No
Wilson et al.6 2009 40 Retrospective
cohort
Baseline, every 3
months until
resuppression, and
every 6 months
thereafter.
Viral load testing was
used as a tool to
assist in patients’
adherence.
Education materials
and a counseling
program were also
offered.
90% of those with
initially raised viral
loads resuppressed
after 3 months,
deﬁned as
,50 copies/mL.
Yes
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80% of drug-resistant transmission could be reduced by yearly
virological monitoring.19 Timing of intervention is crucial. In 1
study included in this review, where routine viral load testing
began later in the treatment cycle, more than 60% patients had
already developed resistance mutations when viral load testing
started,12 suggesting that early viral load monitoring (ie, within
12 months of ART initiation) is critical for identifying early
treatment failure. Of particular note is the 78% resuppression
for patients suspected of failing second-line treatment; robust
third-line options are not widely available in many low-income
countries because of high cost, and viral load may be a partic-
ularly cost-effective intervention for these patients.
Although there is a clear rationale and recommendation
for routine viral load testing, few low-resource countries have
implemented this widely. A recent survey of 23 low- and
middle-income countries found that only 4 incorporated
routine viral load monitoring into their national guidelines,
and only Brazil, Botswana, and South Africa actually have
viral load testing readily available for this purpose.20
As viral load monitoring is expanded, operational
research is needed to inform the optimal adherence interven-
tion, the frequency of viral load testing, the most appropriate
virologic thresholds to use, and the optimal use of point-of-
care technologies.21 The development of simpler, automated
devices (whether point-of-care or laboratory based, using
dried blood spots) is anticipated to greatly enhance the ability
of resource-limited countries to implement viral load testing,
particularly at peripheral sites.7
The aim of this review was to systematically assess the
reported proportion of patients who resuppress following an
adherence intervention, not to determine the causal effect of
viral load on adherence. Such estimates of resuppression should
be taken as indicative only and, in programs, can be expected to
vary according to the presence of drug resistance (which may be
inﬂuenced by regimen efﬁcacy, prior treatment exposure, time
on treatment, and prevalence of transmitted drug resistance)
and the effectiveness of the actual adherence intervention.
Nevertheless, the ﬁndings of this review support the beneﬁt of
viral load testing as a tool to detect adherence problems and to
allow substantial numbers of patients to achieve viral resup-
pression posttargeted adherence counseling. Additional studies
can determine the optimal adherence–counseling package.
In conclusion, these observational studies show that
routine viral load monitoring is beneﬁcial when used as a tool
to identify people in need of adherence interventions, the
majority of whom resuppress and are able to continue their
treatment after adherence support.
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